Ranbaxy Laboratories Limited has informed that its Canadian unit has received final approval in Canada to manufacture and market Ran-Amlodipine Tablets 5 & 10mg (Amlodipine Besylate Tablets) from Health Canada, Therapeutic Products Directorate (TPD).

The drug is indicated and employed as an antihypertensive-antianginal agent.

Reports suggest that, the total generic market size of Amlodipine Besylate Tablets in Canada is $456 million ($CAD).

Ranbaxy Pharmaceuticals-Canada Inc. (RPCI) based in Mississauga, Ontario, Canada, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company.

The overseas firm (RPCI) is engaged in the sale and distribution of generic prescription products in the Canadian healthcare system.

The shares of Ranbaxy Laboratories closed on Monday at Rs 269, up 3% compared to its previous close.